60
Special Populations
Table 24. Drug-Drug Interactions With Statins and
Immunosuppressants and Recommendations for
Management
Immunosuppressant Statin Effect
Cyclosporine/
tacrolimus/
everolimus/
sirolimus*
Atorvastatin Increased statin exposure through multiple
mechanisms.
Increased risk for muscle-related toxicity.
Rosuvastatin
Pravastatin
Fluvastatin
Simvastatin
Lovastatin
Pitavastatin
7.1. Follow-Up Plan and Testing in Stable Patients
COR LOE
Recommendations
2b B-R 1. In stable patients with CCD and with previous ACS or
coronary revascularization, referral to telehealth programs,
community-based programs, or both for lifestyle interventions
may be reasonable as an adjunct to usual care to improve
management of cardiovascular risk factors.
3: No
benefit
B-R 2. In patients with CCD without a change in clinical or functional
status on optimized GDMT, routine periodic testing with
coronary CTA or stress testing with or without imaging is not
recommended to guide therapeutic decision-making.
3: No
benefit
B-R 3. In patients with CCD without a change in clinical or functional
status, routine periodic reassessment of LV function is not
recommended to guide therapeutic decision-making.
3: Harm B-NR 4. In patients with CCD without a change in clinical or functional
status, routine periodic invasive coronary angiography should
not be performed to guide therapeutic decision-making.
Patient Follow-Up: Monitoring and
Managing Symptoms
